Posted by Michael Wonder on 02 Jun 2026
Zenas BioPharma announces submission of biologics license application to US FDA for obexelimab in IgG4-RD
28 May 2026 - BLA submission based on positive results from Phase 3 INDIGO trial.
Zenas BioPharma today announced the submission of its biologics license application to the US FDA for obexelimab in immunoglobulin G4-related disease.
